ContextVision AB (publ)

OB:CONTX Stok Raporu

Piyasa değeri: NOK 260.8m

ContextVision Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 1/6

ContextVision şirketinin kazançları yıllık ortalama -28.6% oranında azalırken, Healthcare Services sektörünün kazançları yıllık 1.6% oranında artan oldu. Gelirler yıllık ortalama 4.5% oranında artan oldu. ContextVision şirketinin öz sermaye getirisi 5.2% olup, net marjı 4.2% dir.

Anahtar bilgiler

-28.61%

Kazanç büyüme oranı

-28.54%

EPS büyüme oranı

Healthcare Services Sektör Büyümesi2.91%
Gelir büyüme oranı4.51%
Özkaynak getirisi5.17%
Net Marj4.18%
Sonraki Kazanç Güncellemesi27 Aug 2026

Yakın geçmiş performans güncellemeleri

Analiz Makalesi Sep 09

We Think That There Are More Issues For ContextVision (OB:CONTX) Than Just Sluggish Earnings

A lackluster earnings announcement from ContextVision AB (publ) ( OB:CONTX ) last week didn't sink the stock price...

Recent updates

Anlatı Güncellemesi Apr 28

CONTX: Liver Biomarker Collaboration Will Sustain Overvaluation Risk For Ultrasound AI

Analysts have adjusted their price targets on ContextVision to reflect updated assumptions on revenue growth, profit margins and future P/E. The new target is now set at NOK X.XX, compared with the previous NOK Y.YY.
Anlatı Güncellemesi Apr 12

CONTX: Liver Biomarker Collaboration Will Support Fair Outlook For Ultrasound AI

Analysts have adjusted their price target on ContextVision to reflect updated assumptions for the discount rate, revenue growth, profit margin and future P/E. The implied fair value estimate now stands at NOK 3.30.
Anlatı Güncellemesi Mar 28

CONTX: Liver Study And Data Quality Program Will Support Fair Future Prospects

Analysts have adjusted their price target for ContextVision to align with a fair value estimate of NOK 3.30 per share, citing slightly updated assumptions for the discount rate and future P/E ratio, while keeping revenue growth and profit margin expectations broadly unchanged. Valuation Changes Fair Value: NOK 3.30 per share remains unchanged in the updated assessment.
Anlatı Güncellemesi Mar 11

CONTX: Liver Study And Data Quality Program Will Support Balanced Future Prospects

Analysts have reduced their fair value estimate for ContextVision from NOK 4.0 to NOK 3.3, citing updated assumptions for revenue growth, profit margins, future P/E levels, and a slightly higher discount rate. Valuation Changes Fair Value: Reduced from NOK 4.0 to NOK 3.3 per share, a modest cut in the equity valuation used in the model.
Anlatı Güncellemesi Feb 24

CONTX: Liver Study And Data Quality Program Will Support Stronger Future Upside

Analysts have raised their price target for ContextVision, citing slightly stronger assumptions on revenue growth, a marginally lower discount rate and a modestly higher future P/E. They have kept fair value and long-term profit margin expectations broadly in line with prior estimates, which together support a higher NOK-based valuation range.
Anlatı Güncellemesi Feb 09

CONTX: Liver Diagnostics Study Progress Will Support Steady Long Term Outlook

Analysts have adjusted their price target for ContextVision to reflect a fair value of $4.00 and a future P/E of 11.34, citing updated assumptions around discount rates and profitability. What's in the News ContextVision started patient enrollment in its clinical development program for liver disease diagnostics at the University of Washington in Seattle, following Institutional Review Board approval and completion of technical setup (Key Developments).
Anlatı Güncellemesi Jan 25

CONTX: Liver Study Progress And Buybacks Will Support Steady Long Term Outlook

Analysts have nudged their price target on ContextVision slightly higher to reflect small updates to fair value, discount rate, revenue growth, profit margin and future P/E assumptions, while keeping their overall outlook broadly unchanged. What's in the News ContextVision started the clinical phase of its liver disease diagnostics program at the University of Washington in Seattle, with the first patient first visit completed following Institutional Review Board approval and technical validation (Key Developments).
Anlatı Güncellemesi Jan 10

CONTX: Share Buybacks And Stable Assumptions Will Support Steady Long Term Outlook

Analysts have slightly adjusted their price target on ContextVision, reflecting modest tweaks to fair value, discount rate, revenue growth, profit margin and future P/E assumptions. They describe the move as a fine tuning of their outlook rather than a major shift in thesis.
Anlatı Güncellemesi Dec 25

CONTX: Share Buybacks Will Support Per Share Metrics With Stable Long Term Outlook

Analysts have nudged their price target on ContextVision slightly higher to reflect modest improvements in long term fair value and profitability assumptions, now estimating the stock to be worth approximately SEK 4.00 per share versus about SEK 4.00 previously. What's in the News Completed a share buyback tranche, repurchasing 1,440,211 shares (equivalent to 1.86% of outstanding capital) between September 5 and September 30, 2025 (Key Developments) Total consideration for the completed buyback program amounted to NOK 6.42 million under the mandate announced on September 15, 2025 (Key Developments) The conclusion of this buyback tranche reduces the free float and may provide incremental support to per share metrics ahead of future results updates (Key Developments) Valuation Changes Fair Value Estimate is effectively unchanged at around SEK 4.00 per share, reflecting only immaterial rounding differences in the model.
Anlatı Güncellemesi Dec 11

CONTX: Share Buybacks Will Support Capital Efficiency With Balanced Long Term Outlook

Analysts have raised their price target for ContextVision slightly, now valuing the shares at roughly SEK 4.00. This reflects modestly higher confidence in the companys long term earnings power, even as underlying model assumptions have changed only marginally.
Anlatı Güncellemesi Nov 27

CONTX: Share Repurchase Program Will Drive Capital Efficiency And Future Upside

Analysts have adjusted their price target for ContextVision slightly upward to $4.00, citing marginal updates to the discount rate as well as modest changes in growth and profitability assumptions. What's in the News ContextVision completed the repurchase of 1,440,211 shares, representing 1.86% of shares, for NOK 6.42 million between September 5 and September 30, 2025.
Analiz Makalesi Nov 19

More Unpleasant Surprises Could Be In Store For ContextVision AB (publ)'s (OB:CONTX) Shares After Tumbling 25%

The ContextVision AB (publ) ( OB:CONTX ) share price has fared very poorly over the last month, falling by a...
Anlatı Güncellemesi Nov 12

CONTX: Share Repurchase Program And Margin Outlook Will Shape Future Performance

Analysts have lowered their price target for ContextVision from $5.00 to $4.00, citing a modest decline in expected revenue growth and a slightly higher discount rate. This adjustment comes despite improved profit margin forecasts.
Analiz Makalesi Nov 09

ContextVision AB (publ) (OB:CONTX) Just Reported, And Analysts Assigned A kr5.00 Price Target

It's been a mediocre week for ContextVision AB (publ) ( OB:CONTX ) shareholders, with the stock dropping 11% to kr3.84...
Analiz Makalesi Sep 09

We Think That There Are More Issues For ContextVision (OB:CONTX) Than Just Sluggish Earnings

A lackluster earnings announcement from ContextVision AB (publ) ( OB:CONTX ) last week didn't sink the stock price...
Analiz Makalesi Aug 30

Earnings Release: Here's Why Analysts Cut Their ContextVision AB (publ) (OB:CONTX) Price Target To kr5.00

ContextVision AB (publ) ( OB:CONTX ) shareholders are probably feeling a little disappointed, since its shares fell...
Anlatı Güncellemesi Aug 09

Future Investments In POCUS And Asian Expansion Will Strengthen Market Presence

The downward revision in ContextVision's price target reflects a notable reduction in expected revenue growth, only partially offset by a modest improvement in profit margins, resulting in a lower fair value estimate of NOK5.00. What's in the News ContextVision entered a research partnership with AMRA Medical to advance AI-powered imaging solutions for metabolic dysfunction-associated steatotic liver disease (MASLD).
Analiz Makalesi May 09

This Broker Just Slashed Their ContextVision AB (publ) (OB:CONTX) Earnings Forecasts

One thing we could say about the covering analyst on ContextVision AB (publ) ( OB:CONTX ) - they aren't optimistic...
Analiz Makalesi Mar 04

There May Be Some Bright Spots In ContextVision's (OB:CONTX) Earnings

The market for ContextVision AB (publ)'s ( OB:CONTX ) shares didn't move much after it posted weak earnings recently...
User avatar
Yeni Anlatı Feb 26

Future Investments In POCUS And Asian Expansion Will Strengthen Market Presence

Expansion into Asian markets and integration with new customers will boost revenues via enhanced customer base and market presence.
Analiz Makalesi Feb 25

Subdued Growth No Barrier To ContextVision AB (publ) (OB:CONTX) With Shares Advancing 25%

ContextVision AB (publ) ( OB:CONTX ) shares have had a really impressive month, gaining 25% after a shaky period...
Analiz Makalesi Feb 15

Is Now An Opportune Moment To Examine ContextVision AB (publ) (OB:CONTX)?

While ContextVision AB (publ) ( OB:CONTX ) might not have the largest market cap around , it saw a significant share...
Analiz Makalesi Sep 02

There May Be Some Bright Spots In ContextVision's (OB:CONTX) Earnings

Shareholders appeared unconcerned with ContextVision AB (publ)'s ( OB:CONTX ) lackluster earnings report last week. Our...
Analiz Makalesi Mar 11

ContextVision AB (publ)'s (OB:CONTX) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/ERatio

ContextVision AB (publ) ( OB:CONTX ) shares have had a horrible month, losing 26% after a relatively good period...
Analiz Makalesi Feb 22

ContextVision's (OB:CONTX) Soft Earnings Are Actually Better Than They Appear

The most recent earnings report from ContextVision AB (publ) ( OB:CONTX ) was disappointing for shareholders. However...
Analiz Makalesi Feb 18

ContextVision AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

It's been a mediocre week for ContextVision AB (publ) ( OB:CONTX ) shareholders, with the stock dropping 17% to kr7.50...
Analiz Makalesi Jan 26

Earnings Not Telling The Story For ContextVision AB (publ) (OB:CONTX)

With a price-to-earnings (or "P/E") ratio of 18.4x ContextVision AB (publ) ( OB:CONTX ) may be sending very bearish...
Analiz Makalesi Jun 22

When Should You Buy ContextVision AB (publ) (OB:CONTX)?

While ContextVision AB (publ) ( OB:CONTX ) might not be the most widely known stock at the moment, it saw a decent...

Gelir ve Gider Dağılımı

ContextVision nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

OB:CONTX Gelir, gider ve kazançlar (SEK Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
31 Mar 261135350
31 Dec 251101360
30 Sep 251144390
30 Jun 251209360
31 Mar 2512313360
31 Dec 2413125340
30 Sep 2412922320
30 Jun 2413226310
31 Mar 2413533300
31 Dec 2313333280
30 Sep 2313537310
30 Jun 2313036290
31 Mar 2312836270
31 Dec 2212333260
30 Sep 2211734180
30 Jun 2211537160
31 Mar 2210635130
31 Dec 2110035100
30 Sep 21945340
30 Jun 21904260
31 Mar 21863580
31 Dec 209538100
30 Sep 20998190
30 Jun 2010010200
31 Mar 2010313200
31 Dec 19957210
30 Sep 199514230
30 Jun 199411250
31 Mar 19935300
31 Dec 1891-1330
30 Sep 1885-2320
30 Jun 1882-3300
31 Mar 1882-2290
31 Dec 1781-2280
30 Sep 1783-1280
30 Jun 17851280
31 Mar 17810260
31 Dec 16824230
30 Sep 16763210
30 Jun 16734190
31 Mar 16725180
31 Dec 15725180
30 Sep 15705170

Kaliteli Kazançlar: CONTX yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: CONTX 'nin mevcut net kar marjları (4.2%) geçen yılın (10.6%) değerinden daha düşüktür.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: CONTX şirketinin kazançları son 5 yılda yılda 28.6% oranında azaldı.

Büyüme Hızlandırma: CONTX 'in son bir yıldır negatif kazanç büyümesi oldu, bu nedenle 5 yıllık ortalamasıyla karşılaştırılamaz.

Kazançlar vs. Sektör: CONTX geçtiğimiz yıl negatif kazanç büyümesine ( -63.8% ) sahipti ve bu da onu Healthcare Services sektör ortalamasıyla ( 1% ) karşılaştırmayı zorlaştırıyordu.


Özkaynak Getirisi

Yüksek ROE: CONTX 'nin Özsermaye Getirisi ( 5.2% ) düşük olarak değerlendiriliyor.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/08/20 11:04
Gün Sonu Hisse Fiyatı2026/08/20 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

ContextVision AB (publ) 3 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Juste SubataviciuteNorne Securities AS
Christian LeePareto Securities
Klas PalinRedeye